ÂÜÀòÂÒÂ×

Dr. Rudoltz is a board-certified radiation oncologist who has been providing clinical development, regulatory, business development, and organizational management expertise to pharmaceutical companies for over 10 years, and was instrumental in taking Imatinib and Qinlock to market. He received an MD from SUNY-Upstate Medical University and completed residency and fellowship training at Thomas Jefferson University and the University of Pennsylvania.